Preparing Compound Other Than Saccharide Containing Alloxazine Or Isoalloxazine Nucleus Patents (Class 435/66)
  • Patent number: 11085060
    Abstract: Provided herein are biocatalysts and systems thereof for pterin-dependent enzymes and pathways and methods of making and using the same. Provided herein in some embodiments are biocatalysts having a pterin source and a pterin-dependent enzymatic pathway biologically coupled to the pterin source. Tetrahydrobiopterin (referred to herein as BH4 or BH 4) can be the pterin source. The BH4 can be synthesized by a tetrahydrobiopterin synthesis pathway. The tetrahydrobiopterin synthesis pathway can include a GTP cyclohydrase; a pyruvoyl tetrahydropterin synthase; a sepiapterin reductase, and/or any combination thereof. The biocatalyst can further contain a pterin-dependent enzymatic pathway. The pterin-dependent enzymatic pathway can be amino acid mono-oxygenase, phenylalanine hydroxylase, tryptophan hydroxylase, tyrosine hydroxylase, nitric oxide synthase, alkylglycerol monooxygenase, and/or any combination thereof.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: August 10, 2021
    Assignee: GEORGIA TECH RESEARCH CORPORATION
    Inventors: Pamela Peralta-Yahya, Amy M. Ehrenworth
  • Patent number: 9963709
    Abstract: The invention provides an organism for expressing foreign DNA, the organism engineered to accept standard DNA carriers. The genome of the organism codes for intracytoplasmic membranes and features an interruption in at least one of the genes coding for restriction enzymes. Further provided is a system for producing biological materials comprising: selecting a vehicle to carry DNA which codes for the biological materials; determining sites on the vehicle's DNA sequence susceptible to restriction enzyme cleavage; choosing an organism to accept the vehicle based on that organism not acting upon at least one of said vehicle's sites; engineering said vehicle to contain said DNA; thereby creating a synthetic vector; and causing the synthetic vector to enter the organism so as cause expression of said DNA.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 8, 2018
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Philip D. Laible, Deborah K. Hanson
  • Publication number: 20150079627
    Abstract: The invention relates to processes of producing a fermentation product, comprising liquefying a starch containing material with an alpha-amylase; pre-saccharifying and/or saccharifying and fermenting using a fermentation organism in the presence of a carbohydrate source generating enzyme and a cellulolytic composition The invention also relates to methods of dewatering whole stillage.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 19, 2015
    Inventors: Thomas Rasmussen, Jeremy Saunders, James Croonenberghs, Zhengfang Kang, Joyce Craig, Michael John Akerman
  • Patent number: 8916359
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 23, 2014
    Assignees: Novozymes A/S, Novozymes North America, Inc.
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Publication number: 20140315243
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein an alpha-amylase, a thermostable protease, and optionally a carbohydrate-source generating enzyme and/or pullulanase, are present and/or added during liquefaction. The invention also relates to compositions suitable for use in a process of the invention.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 23, 2014
    Inventors: Randall Deinhammer, Joyce Craig, Tomoko Matsui, Shinobu Takagi, Suzanne Clark, John Matthews, Anne Glud Hjulmand, Chee-Leong Soong
  • Publication number: 20140206035
    Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.
    Type: Application
    Filed: August 24, 2012
    Publication date: July 24, 2014
    Inventors: Tianqi Sun, Ming Li
  • Patent number: 8759024
    Abstract: The invention relates to processes and means for the biotechnologically fermentative production of riboflavin (hereinafter also referred to as vitamin B2) and means for the implementation of this process, in particular a modified microbial host cell with increased riboflavin yield. The invention thus provides new processes and means for the regulation of the expression of enzyme activities involved in the riboflavin production of the host cell.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: June 24, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Florian Kirchner, Klaus Mauch, Joachim Schmid
  • Patent number: 8722360
    Abstract: The present invention is directed to novel genes mediating the carbon catabolite repression (CCR) of gluconeogenic genes. Furthermore, the polypeptides encoded by said genes as well as the use of said genes in a process for the production of a target fermentation product is provided. Processes for generating such microorganisms are also provided by the present invention. The invention is also related to a genetically engineered microorganism and its use for the production of a target fermentation product, wherein the gluconeogenic genes are relieved from CCR within said microorganism.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 13, 2014
    Assignees: DSM IP Assets B.V., Institute National de la Recherche Agronomique
    Inventors: Stephane Aymerich, Hans-Peter Hohmann, Uwe Sauer
  • Patent number: 8551732
    Abstract: The present invention relates to newly identified mRNA stabilizing elements useful for the production of a target fermentation product, such as e.g. vitamins or enzymes, in particular riboflavin (vitamin B2), biotin, pantothenic acid (vitamin B5), folic acid, thiamin, pyridoxine (vitamin B6), vitamin B12, xylanase, amylase, protease, glucanase, amylomaltase or maltogenic amylase.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: October 8, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Martin Lehmann, Zoltan Pragai, Michéle Schaber
  • Publication number: 20130189731
    Abstract: The present invention relates to a improved process for the biotechnological production of compounds for which ribose-5-phosphate, ribulose-5-phosphate or xylulose-5-phosphate is biosynthetic precursor like riboflavin (vitamin B2), FAD, FMN, pyridoxal phosphate (vitamin B6), guanosine, GMP, adenosine, AMP. The invention further pertains to the generation of the organism producing those compounds. It furthermore relates to the generation of mutated transketolases that allow normal growth on glucose but reduced growth on gluconate when introduced into the production strains and to polynucleotides encoding them.
    Type: Application
    Filed: July 26, 2012
    Publication date: July 25, 2013
    Applicant: DSM IP Assets B.V.
    Inventors: Michael Hans, Dietmar Laudert, Hans-Peter Hohmann, Martin Lehmann
  • Publication number: 20130095522
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein liquefied mash is saccharified or pre-saccharified using a thermostable carbohydrate-source generating enzyme before fermentation or SSF.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 18, 2013
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Randall Deinhammer, Guillermo Coward-Kelly, Ming Li, Junxin Duan, Zheng Liu, Shiro Fukuyama, Keiichi Ayabe
  • Publication number: 20130017571
    Abstract: A truncated pullulanase variant of a parent pullulanase belonging to family GH57 comprising an X47 domain and the use thereof.
    Type: Application
    Filed: December 22, 2010
    Publication date: January 17, 2013
    Applicant: NOVOZYMES A/S
    Inventors: Martin Borchert, Morten Gjermansen, Suzanne Clark, Bernard Henrissat, Maria B. Silow, Peter F. Hallin
  • Publication number: 20120276585
    Abstract: The present invention relates to a method for producing a hydrolysate of from lignocellulose-containing material, comprising pre-treatment with low temperature, hydrolysis and fermentation, wherein hydrolysis is performed by contacting the lignocellulose-containing material with an enzyme composition comprising at least 10% xylanase enzyme protein w/w%.
    Type: Application
    Filed: December 21, 2010
    Publication date: November 1, 2012
    Applicants: COFCO CORPORATION, NOVOZYMES A/S
    Inventors: Haiyu Ren, Dongmin Li, Yun Wang, Chuanji Fang, Hong Zhi Huang
  • Patent number: 8257944
    Abstract: The present invention relates to a improved process for the biotechnological production of compounds for which ribose-5-phosphate, ribulose-5-phosphate or xylulose-5-phosphate is biosynthetic precursor like riboflavin (vitamin B2), FAD, FMN, pyridoxal phosphate (vitamin B6), guanosine, GMP, adenosine, AMP. The invention further pertains to the generation of the organism producing those compounds. It furthermore relates to the generation of mutated transketolases that allow normal growth on glucose but reduced growth on gluconate when introduced into the production strains and to polynucleotides encoding them.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: September 4, 2012
    Assignee: DSM IP Assets B.V.
    Inventors: Michael Hans, Dietmar Laudert, Hans-Peter Hohmann, Martin Lehmann
  • Publication number: 20120214197
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 30, 2010
    Publication date: August 23, 2012
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Publication number: 20120214196
    Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 30, 2010
    Publication date: August 23, 2012
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Publication number: 20110312026
    Abstract: The invention relates to processes and means for the biotechnologically fermentative production of riboflavin (hereinafter also referred to as vitamin B2) and means for the implementation of this process, in particular a modified microbial host cell with increased riboflavin yield. The invention thus provides new processes and means for the regulation of the expression of enzyme activities involved in the riboflavin production of the host cell.
    Type: Application
    Filed: December 15, 2009
    Publication date: December 22, 2011
    Inventors: Florian Kirchner, Klaus Mauch, Joachim Schmid
  • Publication number: 20110312025
    Abstract: The present invention provides an improved biotechnological production of riboflavin (also referred herein as vitamin B2) through modification in the operon containing the riboflavin biosynthetic genes (rib operon), in particular modifications of/in the leader sequences (rib leader) upstream of the corresponding riboflavin biosynthetic genes (rib operon). Furthermore, the present invention relates to genetically engineered microorganisms carrying said modified sequences, processes to generate said modified sequences/microorganisms and the use thereof for production of riboflavin.
    Type: Application
    Filed: November 9, 2009
    Publication date: December 22, 2011
    Inventors: Martin Lehmann, Hans-Peter Hohmann, Dietmar Laudert, Michael Hans
  • Publication number: 20100173356
    Abstract: The present invention relates to newly identified mRNA stabilizing elements useful for the production of a target fermentation product, such as e.g. vitamins or enzymes, in particular riboflavin (vitamin B2), biotin, pantothenic acid (vitamin B5), folic acid, thiamin, pyridoxine (vitamin B6), vitamin B12, xylanase, amylase, protease, glucanase, amylomaltase or maltogenic amylase.
    Type: Application
    Filed: June 9, 2008
    Publication date: July 8, 2010
    Inventors: Martin Lehmann, Zoltan Pragai, Michèle Schaber
  • Patent number: 7670800
    Abstract: The invention relates to a process for the purification of riboflavin comprising the steps of (a) precipitating a first crystalline form of riboflavin, (b) isolating the first crystalline form of riboflavin, (c) transforming the first crystalline form of riboflavin into a second crystalline form of riboflavin under conditions that decompose diluted DNA, and (d) isolating the second crystalline form of riboflavin, provided that at ambient temperature the first crystalline form of riboflavin is thermodynamically less stable than the second crystalline form of riboflavin.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: March 2, 2010
    Assignee: DSM IP Assets B.V.
    Inventor: Arnold Gloor
  • Publication number: 20080311617
    Abstract: The present invention relates to a improved process for the biotechnological production of compounds for which ribose-5-phosphate, ribulose-5-phosphate or xylulose-5-phosphate is biosynthetic precursor like riboflavin (vitamin B2), FAD, FMN, pyridoxal phosphate (vitamin B6), guanosine, GMP, adenosine, AMP. The invention further pertains to the generation of the organism producing those compounds. It furthermore relates to the generation of mutated transketolases that allow normal growth on glucose but reduced growth on gluconate when introduced into the production strains and to polynucleotides encoding them.
    Type: Application
    Filed: October 25, 2006
    Publication date: December 18, 2008
    Inventors: Michael Hans, Dietmar Laudert, Hans-Peter Hohmann, Martin Lehmann
  • Patent number: 7419751
    Abstract: A titanylphthalocyanine crystal having an X-ray diffraction spectrum having plural diffraction peaks and a primary particle diameter not greater than 0.2 ?m, wherein a maximum diffraction peak is observed at a Bragg (2?) angle of 27.2±0.2°; main peaks are observed at 9.4°, 9.6° and 24.0°; and a minimum diffraction peak is observed at 7.3°; and preferably no diffraction peak is observed at an angle greater than 7.3° and less than 9.4° when a specific X-ray of CuK? having a wavelength of 1.542 ? irradiates the titanylphthalocyanine crystal.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: September 2, 2008
    Assignee: Ricoh Company, Ltd.
    Inventor: Tatsuya Niimi
  • Patent number: 7344855
    Abstract: A process for the preparation of a target fermentation product comprising cultivation of an aerobic microorganism to produce such product, wherein in the microorganism the efficiency of the respiratory chain is increased, transformed and novel nucleotide sequences.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: March 18, 2008
    Assignee: DSM IP Assets B.V.
    Inventors: Hans-Peter Hohmann, Nigel John Mouncey, Uwe Sauer, Nicola Zamboni
  • Patent number: 7166456
    Abstract: Riboflavin-producing Bacillus subtilis which is resistant to proline analogue, and a method for producing riboflavin using the Bacillus subtilis are provided.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: January 23, 2007
    Assignee: CJ Corp.
    Inventors: Kwang Ho Lee, Young Hoon Park, Jong Kwon Han, Jang Hee Park, Kyung Han Lee, Hyang Choi
  • Patent number: 7078222
    Abstract: Riboflavin-producing Bacillus subtilis which is resistant to threonine analogue, and a method for producing riboflavin using the Bacillus subtilis are provided. The subject Bacillus subtilis referred to as Bacillus subtilis CJKB0002 has the accession number KCCM-10446, having been deposited in Korean Culture Center of Microorganisms (KCCM), 361-221, Yurim B/D, Hongie-1-dong, Seodaemun-gut, Seoul 120-091 Republic of Korea, on Nov. 18, 2002.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: July 18, 2006
    Assignee: CJ Corp.
    Inventors: Kwang Ho Lee, Young Hoon Park, Jong Kwon Han, Jang Hee Park, Kyung Han Lee, Hyang Choi
  • Publication number: 20040214261
    Abstract: The invention provides a process of producing bio-available folate, i.e. folic acid having an increased portion of monoglutamyl folate and a decreased proportion of polyglutamyl folate, by culturing food-grade micro-organisms containing an active heterologous or homologous polyglutamyl hydrolase activity or containing increased activities of folate biosynthesis enzymes. The genes encoding the polyglutamyl hydrolase and the folate biosynthesis enzymes may be of various origin, e.g. from rodents or other mammals including man. Also provided is a foodstuff, especially a dairy product containing such monoglutamyl folate-producing micro-organisms.
    Type: Application
    Filed: June 7, 2004
    Publication date: October 28, 2004
    Inventors: Wilbert Feike Henricus Sybesma, Igor Mierau, Maria Johanna Catharina Starrenburg, Michiel Kleerebezem, Willem Meindert De Vos
  • Publication number: 20040110248
    Abstract: Riboflavin-producing Bacillus subtilis which is resistant to threonine analogue, and a method for producing riboflavin using the Bacillus subtilis are provided.
    Type: Application
    Filed: June 4, 2003
    Publication date: June 10, 2004
    Inventors: Kwang Ho Lee, Young Hoon Park, Jong Kwon Han, Jang Hee Park, Kyung Han Lee, Hyang Choi
  • Publication number: 20040110249
    Abstract: Riboflavin-producing Bacillus subtilis which is resistant to proline analogue, and a method for producing riboflavin using the Bacillus subtilis are provided.
    Type: Application
    Filed: June 4, 2003
    Publication date: June 10, 2004
    Inventors: Kwang Ho Lee, Young Hoon Park, Jong Kwon Han, Jang Hee Park, Kyung Han Lee, Hyang Choi
  • Publication number: 20040043458
    Abstract: The invention relates to coryneform bacteria which, instead of the singular copy of an open reading frame (ORF), gene or allele naturally present at the particular desired site (locus), have at least two copies of the open reading frame (ORF), gene or allele in question, preferably in tandem arrangement, and optionally at least a third copy of the open reading frame (ORF), gene or allele in question at a further gene site, and processes for the preparation of chemical compounds by fermentation of these bacteria.
    Type: Application
    Filed: February 5, 2003
    Publication date: March 4, 2004
    Applicant: Degussa AG
    Inventors: Brigitte Bathe, Caroline Kreutzer, Bettina Mockel, Georg Thierbach
  • Publication number: 20040014167
    Abstract: The present invention provides a transformed cell which is transformed by at least one gene of enzymes participating in biosynthesis of tetrahydrobiopterin and a process for the production of a biopterin compound using the same. In accordance with the present invention, the biopterin compound can be produced in large quantities in an industrial advantageous manner from less expensive materials.
    Type: Application
    Filed: April 26, 2003
    Publication date: January 22, 2004
    Inventors: Masayuki Yabuta, Kazuaki Furukawa, Nobue Miyamoto, Katsuhiko Yamamoto, Kazuhiro Ohsuye
  • Publication number: 20030232406
    Abstract: Vectors and recombinant bacteria for overproducing riboflavin, in which nucleic acid overproducing riboflavin biosynthetic proteins is introduced in the chromosome of the host organism, e.g. at multiple sites and in multiple copies per site. A rib operon having at least five genes is used to make such recombinant bacteria.
    Type: Application
    Filed: February 10, 2003
    Publication date: December 18, 2003
    Applicant: ROCHE VITAMINS, INC.
    Inventors: John B. Perkins, Alan Sloma, Janice G. Pero, Randolph T. Hatch, Theron Hermann, Thomas Erdenberger
  • Publication number: 20030219881
    Abstract: The invention relates to coryneform bacteria which have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, in each case a second, optionally third or fourth copy of this open reading frame (ORF), gene or allele at in each case a second, optionally third or fourth site in a form integrated into the chromosome and processes for the preparation of chemical compounds by fermentation of these bacteria.
    Type: Application
    Filed: February 5, 2003
    Publication date: November 27, 2003
    Applicant: Degussa AG
    Inventors: Bathe Brigitte, Kreutzer Caroline, Mockel Bettina, Thierbach Georg
  • Publication number: 20030170775
    Abstract: The invention relates to a process for producing corynebacteria comprising one or more modified genomic sequences, where a vector is used which does not replicate in corynebacteria and whose nucleic acid is not recognized by corynebacteria as foreign.
    Type: Application
    Filed: March 12, 2003
    Publication date: September 11, 2003
    Inventors: Markus Pompejus, Hartwig Schroder, Burkhard Kroger, Oskar Zelder
  • Publication number: 20030082815
    Abstract: This invention is directed to the transformation of the flavinogenic yeasts, Pichia guilliermondii and Candida famata, and mutants thereof, by electroporation (electrotransformation) and by spheroplast transformation. The invention is also directed to nucleic acid constructs such as vectors, plasmids, and ARS sequences which transform flavinogenic yeasts, and mutants thereof, at a high level and in a stable manner so as to result in stably transformed yeast host cells which express/produce recombinant products. This invention also is directed to flavinogenic yeasts, Pichia guilliermondii and Candida famata, and mutants and temperature sensitive mutants thereof, which produce or overproduce riboflavin.
    Type: Application
    Filed: July 13, 2001
    Publication date: May 1, 2003
    Inventors: Charles Abbas, Andrii Y. Voronovsky, Liubov R. Fayura, Barbara V. Kshanovska, Kostiantyn V. Dmytruk, Kateryna A. Sibirna, Andrii A. Sibirny
  • Patent number: 6551813
    Abstract: Vectors and recombinant bacteria for overproducing riboflavin, in which nucleic acid overproducing riboflavin biosynthetic proteins is introduced in the chromosome of the host organism, e.g. at multiple sites and in multiple copies per site. A rib operon having at least five genes is used to make such recombinant bacteria.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: April 22, 2003
    Assignee: Roche Vitamins Inc.
    Inventors: John B. Perkins, Alan Sloma, Janice G. Pero, Randolph T. Hatch, Theron Hermann, Thomas Erdenberger
  • Patent number: 6451545
    Abstract: Provided are a monoclonal antibody making it possible to detect a native fibrin monomer, which is produced at the initial state of blood coagulation, and soluble fibrin; a hybridoma; and an immunoassay for detecting the initial stage of blood coagulation with high sensitivity, quickly, using the monoclonal antibody. Using a fibrinogen analog in blood as an immune source, cell fusion is carried out to prepare a monoclonal antibody which is not reactive with fibrinogen and is specifically and simultaneously reactive with a native fibrin monomer (that is, a fibrin monomer which is present in a body fluid, in particular in blood, and is not solubilized) and soluble fibrin. The fibrin monomer analog is preferably fibrinogen treated with bathroxobin, which is a snake venom.
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: September 17, 2002
    Assignee: Nissui Pharmaceutical Co., Ltd.
    Inventors: Seiji Tanaka, Akiei Hamano, Mamoru Umeda
  • Patent number: 6322995
    Abstract: The present invention provides a recombinant bacterium for the over-production of riboflavin. The recombinant bacterium has has been transformed by three or four vectors, two of which each comprise either a DNA sequence coding for the riboflavin synthesizing enzymatic activities of Bacillus subtilis or a DNA sequence which is substantially homologous and one or more transcription elements and a third and/or fourth vector comprising either a DNA sequence coding for the ribA gene product of Bacillus subtilis or a DNA sequence which is substantially homologous and optionally a transcription element whereby one or a plurality of copies of each of these vectors has/have been integrated at three or four different sites within the bacterium's chromosome.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: November 27, 2001
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Hans-Peter Hohmann, Markus Hümbelin, Adolphus van Loon, Walter Schurter
  • Patent number: 6258554
    Abstract: An industrially more advantageous method for the production of metabolites biologically synthesized via phosphoribosyl pyrophosphate (PRPP) is provided, making use of metabolically modified strains in which transketolase activity is deficient or reduced in comparison with the parent strain.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: July 10, 2001
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Masato Ikeda, Kazuyuki Okamoto, Tetsuo Nakano, Nozomu Kamada
  • Patent number: 5981212
    Abstract: A process for increasing the riboflavin content in spray-dried discharges from riboflavin fermentations comprises inducing the lysis of the cells contained in the fermentation discharge by specific production or activation of enzymes which break down the cell walls and proteins. This autolysis can be induced in the riboflavin-producing strains of Ashbya gossypii, Eremothecium ashbyii and other microorganisms by incubation at from 35 to 55.degree. C. with substantial exclusion of oxygen for from 6 to 28 hours.
    Type: Grant
    Filed: November 20, 1991
    Date of Patent: November 9, 1999
    Assignee: BASF Aktiengesellschaft
    Inventor: Roland Kurth
  • Patent number: 5925538
    Abstract: Vectors and recombinant bacteria for overproducing riboflavin, in which nucleic acid overproducing riboflavin biosynthetic proteins is introduced in the chromosome of the host organism, e.g. at multiple sites and in multiple copies per site. A rib operon having at least five genes is used to make such recombinant bacteria.
    Type: Grant
    Filed: August 24, 1998
    Date of Patent: July 20, 1999
    Assignee: Roche Vitamins Inc.
    Inventors: John B. Perkins, Alan Sloma, Janice G. Pero, Randolph T. Hatch, Theron Hermann, Thomas Erdenberger
  • Patent number: 5837528
    Abstract: Vectors and recombinant bacteria for overproducing riboflavin, in which nucleic acid overproducing riboflavin biosynthetic proteins is introduced in the chromosome of the host organism, e.g. at multiple sites and in multiple copies per site. A rib operon having at least five genes is used to make such recombinant bacteria.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 17, 1998
    Assignee: Hoffmann La Roche, Inc.
    Inventors: John B. Perkins, Alan Sloma, Janice G. Pero
  • Patent number: 5821090
    Abstract: The present invention relates to the genes for riboflavin biosynthesis in the fungus Ashbya gossypii and to genetic engineering processes for preparing riboflavin using these genes and gene products.
    Type: Grant
    Filed: September 24, 1996
    Date of Patent: October 13, 1998
    Assignee: BASF Aktiengesellschaft
    Inventors: Jose Luis Revuelta Doval, Maria Jose Buitrago Serna, Maria Angeles Santos Garcia
  • Patent number: 5589355
    Abstract: The present invention provides a process for producing riboflavin efficiently at a low cost, wherein riboflavin is formed and accumulated in a medium by culturing a microorganism carrying a recombinant DNA prepared by inserting into a vector DNA a DNA which is derived from a microorganism belonging to the genus Corynebacterium or Brevibacterium and which, upon introduction into a riboflavin-requiring microorganism, confers on the microorganism the ability to complement its riboflavin requirement.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 31, 1996
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Satoshi Koizumi, Yoshiyuki Yonetani, Sadao Teshiba
  • Patent number: 5460961
    Abstract: A substantially pure recombinant human myeloperoxidase heme-containing precursor, comprising a glycoprotein of 84 KD with the amino acid sequence coded for by the nucleotide sequence from 145 to 2235 corresponding to codons 49 to 745 in phase after the first methionine codon in FIG. 1 produced by culturing prokaryotic or eukaryotic cells transformed by a vector for the expression of human myeloperoxidase precursor in said cells.
    Type: Grant
    Filed: January 16, 1991
    Date of Patent: October 24, 1995
    Assignee: La Region Wallonne
    Inventors: Carol Deby, Joel Pincemail, Alex Bollen
  • Patent number: 5418157
    Abstract: Genetically engineered E. coli carry vectors containing inserts that code for Clostridium histolyticum collagenase. These inserts code for: (a) a form of collagenase having a molecular weight of about 68,000 daltons in the essential absence of larger forms of collagenase; (b) the 68 kd form of collagenase and a fusion polypeptide consisting of the collagenase protein fused to at least a portion of the .beta.-galactosidase protein of E. coli or (3) the 68 kd form of collagenase and polypeptides of molecular weight of from above about 68,000 daltons to about 100,000 daltons and having the enzymatic activity of C. histolyticum collagenase as indicated by digestion of .sup.3 H-acetylated collagen and by specific inhibition by 1,10-phenanthroline plus EDTA. The collagenase genes in the transformed E. coli are expressed efficiently in the transformed cells to yield enzymatically active and immunologically cross-reactive collagenase.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: May 23, 1995
    Inventors: Hun-Chi Lin, Shau-Ping Lei
  • Patent number: 5334510
    Abstract: The present invention provides a process for producing riboflavin by fermentation, a method for providing microorganisms having an improved riboflavin-producing capability, and strains of microorganisms having improved riboflavin-producing ability. The strains of the present invention belong to the genus Bacillus, have reduced activity of hydrolysing phosphoric acid from 5'-guanylic acid, and have the ability of producing riboflavin. Mutants used in the processes of this invention have an improved ability of producing riboflavin and are capable of producing or accumulating a large amount of riboflavin in the culture medium. The processes of this invention are therefore suitable for producing riboflavin in an effective manner at a low cost.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: August 2, 1994
    Assignee: Ajinomoto Co., Inc.
    Inventors: Naoki Usui, Yoko Yamamoto, Tuyoshi Nakamatu
  • Patent number: 5231007
    Abstract: A method of systematically generating and isolating highly flavinogenic strains of Candida famata. The strains Candida famata GA18Y8-6#2 dgr and Candida famata GA18Y8-6#2#11 have been developed and produce yields of ca. 7.0 to 7.5 grams per liter per 6 days. The method includes a combination of iterative mutagenizing steps and protoplast fusion steps performed on the parent strain and the descendant strains which are selected following each step according to a screening protocol.
    Type: Grant
    Filed: August 15, 1991
    Date of Patent: July 27, 1993
    Assignee: Zeagen, Inc.
    Inventors: Donald L. Heefner, Annette Boyts, Linda Burdzinski, Michael Yarus
  • Patent number: 5210023
    Abstract: A method of purifying ferment-produced riboflavin, wherein the impure riboflavin is suspended in water or dilute aqueous acid, and the suspension is heated at a temperature of from 75.degree. to 130.degree. C. for from 0.3 to 3 hours with stirring, during which time crystal transformation takes place, after which the mixture is cooled and the purified product is isolated in known manner.
    Type: Grant
    Filed: July 1, 1991
    Date of Patent: May 11, 1993
    Assignee: BASF Aktiengesellschaft
    Inventors: Johannes Grimmer, Hans Kiefer, Christoph Martin
  • Patent number: 5169759
    Abstract: Riboflavin is removed from fermentation suspensions by them being heated at from 50.degree. to 90.degree. C. for from 1 to 3 hours, than cooled to from 0.degree. to 30.degree. C. over a period of from 1 to 5 hours, and subsequently being centrifuged to give a sediment fraction and liquid fraction in such a way that the sediment fraction contains predominantly riboflavin crystals as solid, and the liquid fraction contains virtually no crystalline riboflavin, and, where appropriate, resuspending the sediment fraction in from 0.5 to 2 parts by volume of water per part by volume of sediment fraction and repeating procedure c.
    Type: Grant
    Filed: January 23, 1991
    Date of Patent: December 8, 1992
    Assignee: BASF Aktiengesellschaft
    Inventors: Tillmann Faust, Joachim Meyer, Georg Wellinghoff, Walter Gosele, Christoph Martin, Johannes Grimmer
  • Patent number: 5164303
    Abstract: Strains of yeast of the species Candida famata are disclosed which can produce 10 grams of riboflavin per liter in 6 days, and in particular, strains identified by ATCC Accession Nos. 20849 and 20850. Riboflavin yields of more than 20 grams per liter in 200 hours have been achieved. Strains of the present invention have increased sensitivity to iron inhibition of flavinogenesis and have enhanced riboflavin production per cell at increased iron concentrations in the fermentation medium. The invention also is directed toward a process for selecting improved microorganisms which are resistant to inhibition of growth by depleted medium. Such selected mircoorganisms are then tested for riboflavin overproduction. The present invention is also directed toward a selection process in which mutated microorganisms are cultured in the presence of tubercidin, a purine analog. Mutant strains resistant to tubercidin are then tested for riboflavin over-production.
    Type: Grant
    Filed: February 15, 1990
    Date of Patent: November 17, 1992
    Assignee: ZeaGen, Inc.
    Inventors: Donald L. Heefner, Craig A. Weaver, Michael J. Yarus, Linda A. Burdzinski